The Preliminary Study For Cloning, Expression And Biological Activity Identification Of GX1-rmhTNFα

Tumor angiogenesis research has become one of the most promising and actively explored fields for new anticancer therapies. Antigiogenesis as a therapy has two significant advantages: easy accessibility and non-drug resistance. Most importantly, both structural and functional differences exist among blood vessels in different tissues and tumor types. So molecules that are able to effectively deliver therapeutic agents to the tumor microenvironment thus represent promising and important new tools for cancer therapy.We have obtained a specific molecule code, GX1, for gastric cancer by using phage displayed peptide library screening in vivo. Immunohistochemistry of mouse and human tissue showed that this phage peptide could bind to the endothelial cells of human gastric cancer. This observation paved the way for the synthetic peptide's use in therapeutic approaches entailing the selective delivery of toxic agents or drugs to gastric tumor vasculature.